MXPA04004131A - Hepta-, octa- and nonapeptides having antiangiogenic activity. - Google Patents

Hepta-, octa- and nonapeptides having antiangiogenic activity.

Info

Publication number
MXPA04004131A
MXPA04004131A MXPA04004131A MXPA04004131A MXPA04004131A MX PA04004131 A MXPA04004131 A MX PA04004131A MX PA04004131 A MXPA04004131 A MX PA04004131A MX PA04004131 A MXPA04004131 A MX PA04004131A MX PA04004131 A MXPA04004131 A MX PA04004131A
Authority
MX
Mexico
Prior art keywords
nonapeptides
hepta
octa
antiangiogenic activity
compounds
Prior art date
Application number
MXPA04004131A
Other languages
Spanish (es)
Inventor
Haviv Fortuna
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/000,681 external-priority patent/US20030125259A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA04004131A publication Critical patent/MXPA04004131A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
MXPA04004131A 2001-10-31 2002-10-30 Hepta-, octa- and nonapeptides having antiangiogenic activity. MXPA04004131A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/000,681 US20030125259A1 (en) 2001-10-31 2001-10-31 Octa- and nonapeptides having antiangiogenic activity
US10/263,812 US20030096758A1 (en) 2001-10-31 2002-10-04 HEPTA-, OCTA- and nonapeptides having antiangiogenic activity
PCT/US2002/034811 WO2003037268A2 (en) 2001-10-31 2002-10-30 Hepta-, octa- and nonapeptides having antiangiogenic activity

Publications (1)

Publication Number Publication Date
MXPA04004131A true MXPA04004131A (en) 2004-07-08

Family

ID=26667985

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004131A MXPA04004131A (en) 2001-10-31 2002-10-30 Hepta-, octa- and nonapeptides having antiangiogenic activity.

Country Status (11)

Country Link
EP (1) EP1451210A4 (en)
JP (1) JP4362064B2 (en)
CN (1) CN1639188A (en)
BR (1) BR0209758A (en)
CA (1) CA2466170C (en)
IL (1) IL161527A0 (en)
MX (1) MXPA04004131A (en)
NZ (1) NZ532367A (en)
PL (1) PL374238A1 (en)
TW (1) TWI268934B (en)
WO (1) WO2003037268A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
EP1075494A2 (en) * 1998-05-05 2001-02-14 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
BR9910639A (en) * 1998-05-22 2002-01-15 Abbott Lab Anti-angiogenic drugs comprising peptide

Also Published As

Publication number Publication date
CA2466170A1 (en) 2003-05-08
TW200302832A (en) 2003-08-16
IL161527A0 (en) 2004-09-27
EP1451210A4 (en) 2009-05-27
PL374238A1 (en) 2005-10-03
WO2003037268A3 (en) 2003-09-12
TWI268934B (en) 2006-12-21
BR0209758A (en) 2005-10-04
CN1639188A (en) 2005-07-13
NZ532367A (en) 2006-01-27
JP4362064B2 (en) 2009-11-11
JP2005512981A (en) 2005-05-12
CA2466170C (en) 2011-04-05
EP1451210A2 (en) 2004-09-01
WO2003037268A2 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA05006196A (en) Compounds and methods for the treatment or prevention of flavivirus.
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
DE60112609D1 (en) Pyrazolopyridine
AU2002360592A8 (en) Inhibitors of hepatitis c virus
NO20003233L (en) 4-hydroxyquinoline-3-carboxamides and hydrazides as antivirals
GB0225475D0 (en) Therapeutic agents
AP2003002915A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
MXPA03008623A (en) Pharmaceutical combinations for the treatment of cancer.
BR9708114A (en) Xanthone analogues for the treatment of infectious diseases.
DE60112330D1 (en) Pyrazolopyridinderivate
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
MXPA04004134A (en) Tri-, tetra-, and penta-peptides having antiangiogenic activity.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
EP0932613A4 (en) Blocking expression of virulence factors in s. aureus
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
IL165259A0 (en) Compounds useful in the treatment of anthraxa and inhibiting lethal factor
MXPA04000805A (en) Peptides having antiangiogenic activity.
WO2004054513A3 (en) Methods and compositions for treating and preventing ear infections
WO2003072053A3 (en) Compounds for treatment of copper overload
MXPA04004131A (en) Hepta-, octa- and nonapeptides having antiangiogenic activity.
MXPA04004132A (en) Hexa-, hepta-, and octapeptides having antiangiogenic activity.
MXPA04004133A (en) Di-, tri,- and tetra-peptides having antiangiogenic activity.
MXPA04004135A (en) Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights